- TD-A Brief Overview of the More Common Indications for Lab Studies
- TD-Advanced Procedures with RadioFrequency
- TD-Age Related Macular Degeneration - 2022 Update
- TD-Beauty Confidential
- TD-Beyond the Posterior Pole
- TD-Contemporary Diabetic Retinopathy Care
- TD-Eyelid Ptosis: Make the Right Diagnosis
- TD-Imaging the Anterior Segment
- TD-Innovations in Ocular Surface Disease to Maximize Patient Outcomes
- TD-Lids and Lashes on the Cutting Edge
- TD-Minor Surgical Procedures
- TD-Optometry & Genetics: The Future of Precision Medicine
- TD-Peeling Back the Layers: A Case Based Trip Around the Cornea
- TD-Screening for Carcinoma of the Eyelids
- TD-Seeing White Dots
- TD-Sensitivity Training; A Chronicle of Neurotrophic Keratitis (NK) Management
- TD-The Complete Course on Corneal Dystrophies and Degenerations
- TD-The Ocular Adnexa. Optometry's Next Frontier
- TD-Using IPL to address ocular surface and adnexal conditions
TD-Panel Discussion: Is There a Treatment for Me? Genetic Testing, Clinical Trials, Gene Therapy, & Future Treatments Q&A
The recent developments in genetics research have led to an incredible growth in our understanding of ocular conditions, leading to the 2017 FDA approval of the first groundbreaking gene therapy and the ongoing development of new gene therapies for numerous inherited retinal dystrophies. Our increased understanding of the genetics of eye conditions expands the opportunities for eye care practitioners to provide patients with more specific diagnoses, more accurate assessment of prognoses, and improved counseling. This includes the ability to deliver gene-specific patient education on eligibility for gene therapy and gene therapy clinical trials. This panel presentation and discussion will provide an introductory level overview of the most common patient questions and answers surrounding genetic testing and gene therapy. We will cover the current state of gene therapy as well as other ongoing clinical trials, including developments in CRISPR gene editing, optogenetics, and antisense oligonucleotide-based therapy. Focus will be placed on covering the information optometrists can provide to patients to help them make the best informed decisions about their ocular management. We will also discuss the ramifications of gene therapy for the future of low vision rehabilitation and ocular health management. Attendees will be provided with resources to stay up-to-date with genetics information and clinical trials.
Rachelle Lin, O.D.
Ben Shaberman, O.D.
Jill Dolgin, PharmD
AOA Expiration Date:
Doctors of optometry challenge reasoning behind proposed Eyeglass Rule changes at FTC workshop
The recent workshop heard testimony from various stakeholders on the potential impact that proposed changes to the Eyeglass Rule might have on consumer choice and the burden on the practices of doctors of optometry and ophthalmology, which are already understaffed and saddled with other federal regulation. The Federal Trade Commission will use the feedback to determine whether to go forward with its recommendations.
Common coding Qs answered
These are the coding questions your colleagues are asking—and the answers from the AOA’s experts could help you.
The heat is on: Ensure patients’ protective eyewear is, too
Some doctors of optometry may see an increase in patients seeking care during the summer months, whether they’re playing sports or battling dry air conditions. Be prepared to share your expertise.